title: A single center experience with bone marrow transplantation for high risk neuroblastoma.
authors.affiliation: Coordination Center EBMT Registry, Lyon, France.
authors.forename: R
authors.initials: R
authors.lastname: Ladenstein
authors.forename: C
authors.initials: C
authors.lastname: Lasset
authors.forename: E
authors.initials: E
authors.lastname: Bouffet
authors.forename: M
authors.initials: M
authors.lastname: Brunat-Mentigny
authors.forename: P
authors.initials: P
authors.lastname: Biron
authors.forename: I
authors.initials: I
authors.lastname: Philip
authors.forename: F
authors.initials: F
authors.lastname: Chauvin
authors.forename: T
authors.initials: T
authors.lastname: Philip
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D016190:Carboplatin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D012074:Remission Induction; D012086:Reoperation; D015996:Survival Rate; D013713:Teniposide / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D009944:Organoplatinum Compounds; C055423:didimethylsulfoxide dichloroplatinum(II); D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D013713:Teniposide; D016190:Carboplatin; D002330:Carmustine